Clementia is a privately held clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for people living with rare diseases by exploiting the science of novel retinoic acid receptor gamma agonists to address bone diseases, including Fibrodysplasia Ossificans Progressiva (FOP).